What was the primary driver of sales growth in the first quarter of 2007?

The primary driver of sales growth was a strong performance in the Critical Care segment, which increased by 12.1%, and continued growth in the Heart Valve Therapy segment, up 3.5%. These were supported by new product introductions and favorable foreign exchange rates.

How is the company addressing the FDA concerns regarding its Irvine facility?

Edwards Lifesciences submitted a response to the FDA's Warning Letter in March 2007, which the FDA has deemed adequate. This means the FDA will not defer approval of pending pre-market submissions or export certificates for products manufactured at the Irvine facility.

What is the significance of the PARTNER trial?

The PARTNER trial is a pivotal clinical trial for Edwards Lifesciences' Edwards SAPIEN Transcatheter Heart Valve (THV) technology. It will evaluate the THV in patients at high risk for conventional open-heart valve surgery, marking a significant step in the development of transcatheter valve replacement therapies.

Why did net income decrease year-over-year despite sales growth?

Net income decreased from $45.9 million in the first quarter of 2006 to $33.2 million in the first quarter of 2007. This was largely due to the absence of a significant one-time gain of $23.8 million recorded in the prior year from a patent settlement with Medtronic. Excluding special items, the underlying profitability trends are more stable.

EW 10-Q Quarterly Report Q1 FY2007 — Revenue, Net Income, EPS

Summary

Edwards Lifesciences Corporation (EW) reported steady revenue growth in the first quarter of 2007, with total net sales reaching $264.1 million, a 2.9% increase year-over-year. This growth was primarily driven by a strong performance in the Critical Care segment, which saw a 12.1% increase in sales, and a 3.5% rise in Heart Valve Therapy, its largest segment. The company is actively investing in its future, particularly in transcatheter valve development, with the PARTNER trial for its SAPIEN THV technology commencing. Management has also successfully addressed FDA concerns regarding quality systems at its Irvine facility, a positive development for ongoing product approvals. Financially, the company maintained solid profitability, although net income saw a decline compared to the prior year, partly due to the absence of a significant one-time gain from a patent settlement recorded in Q1 2006. Operating cash flow was lower year-over-year, largely because of the non-recurrence of the patent settlement payment. The company continues to manage its debt and returned capital to shareholders through stock repurchases, demonstrating a focus on operational execution and strategic investments in innovation.

Key Highlights

1Total net sales increased by 2.9% to $264.1 million for the first quarter of 2007 compared to the same period in 2006.
2Critical Care segment sales grew significantly by 12.1%, driven by the FloTrac system and pressure monitoring products.
3Heart Valve Therapy, the largest segment, saw a 3.5% increase in net sales, supported by premium valve products like the PERIMOUNT Magna.
4The company initiated the pivotal PARTNER trial for its Edwards SAPIEN Transcatheter Heart Valve (THV) technology.
5The FDA has accepted Edwards Lifesciences' response to a previously issued Warning Letter regarding quality systems at its Irvine facility.
6Net income decreased to $33.2 million from $45.9 million in the prior year's quarter, influenced by the absence of a large patent settlement gain.
7The company continued its share repurchase program, buying back 0.5 million shares for $24.8 million in the first quarter of 2007.

Edwards Lifesciences Corp Quarterly Report for Q1 Ended Mar 31, 2007

Summary

Key Highlights

Frequently Asked Questions